Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.86 USD | -3.62% | -1.47% | +55.90% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.90% | 1.78B | |
+18.46% | 125B | |
+14.15% | 109B | |
-2.98% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.00% | 16.64B | |
-0.04% | 13.45B | |
+22.65% | 11.32B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc., Q4 2018 Earnings Call, Mar 07, 2019